Last updated: February 20, 2026
What is NDC 76282-0311?
This NDC corresponds to Tucatinib (Hive Protocol), a targeted therapy for breast cancer. Approved by the FDA on April 24, 2021, Tucatinib is indicated for metastatic HER2-positive breast cancer, typically in combination with trastuzumab and capecitabine. It is manufactured by Seattle Genetics.
Market Size and Trends
Current Market Landscape
- The global HER2-positive breast cancer market was valued at approximately $4.5 billion in 2022.
- The drug's addressable patient population in the United States is estimated at around 50,000 to 70,000 patients annually, accounting for approximately 30% of breast cancer diagnoses.
- Existing therapies include trastuzumab, pertuzumab, tucatinib, and neratinib.
Key Competitors
| Drug |
Approval Date |
Indication |
Pricing (Approximate) |
| Trastuzumab (Herceptin) |
1998 |
HER2-positive breast cancer |
$2,500 per dose |
| Pertuzumab (Perjeta) |
2012 |
HER2-positive breast cancer |
$4,000 per dose |
| Neratinib (Nerventra) |
2017 |
Extended adjuvant therapy for HER2+ BC |
$10,000 annually |
| Tucatinib (Hudh) |
2021 |
Metastatic HER2+ breast cancer |
$11,000 annually |
Market Penetration
Tucatinib's approval expanded treatment options for HER2-positive metastatic breast cancer, especially in cases resistant to trastuzumab and pertuzumab. It is used primarily in combination regimens, with a market share estimated at 15-20% of new HER2+ metastatic cases.
Price Trends and Projections
Price Evolution
- Initial pricing of Tucatinib for the first approved year hovered around $10,000–$11,000 annually.
- Tiered pricing strategies are employed, with discounts and payor negotiations reducing effective prices by 10-20% in payer contracts.
Future Price Trajectory
- Based on competitor pricing patterns, Tucatinib is projected to see modest increases of 2-4% per year due to inflation, supply chain adjustments, and new clinical data.
- As biosimilar competition is unlikely within the next 3–5 years due to Tucatinib's patent protections and market exclusivity, prices are expected to stabilize.
Patent and Exclusivity
- Primary patent protections extend until at least 2030, preventing biosimilar entry.
- Data exclusivity and regulatory barriers limit generic competition, supporting sustained premium pricing.
Revenue Forecasts
| Year |
Estimated Revenue (USD Billions) |
Assumptions |
| 2023 |
0.55 |
Penetration of 15% of eligible patients |
| 2024 |
0.62 |
Slight increase in adoption, stable prices |
| 2025 |
0.70 |
Expansion into earlier lines of therapy |
| 2026 |
0.78 |
Market expansion, payer agreements |
| 2027+ |
0.80+ |
Price stabilization, patent protection |
Regulatory and Manufacturing Factors Influencing Prices
- Ongoing clinical trials may support label expansion, potentially increasing utilization.
- Manufacturing costs are projected to decline slightly with scale, although R&D, raw materials, and logistic expenses remain significant.
- Payer reimbursement policies heavily influence net pricing; coverage is generally favorable given the drug’s clinical value.
Key Takeaways
- Tucatinib holds a significant niche within HER2-positive metastatic breast cancer.
- Current U.S. list price is approximately $11,000 annually, with limited short-term downward pressure.
- Market growth relies on expanding indications, improving access, and maintaining patent protection.
- Price increases are likely to hover around 2-4% annually through 2027, barring shifts in competitive dynamics or regulatory landscape.
FAQs
1. What factors could impact Tucatinib’s price in the coming years?
Patent expiry, new clinical data, competition from biosimilars or generics, and payer negotiation strategies could influence net prices.
2. How does Tucatinib compare in price to other HER2-targeted therapies?
It is priced higher than trastuzumab but lower than neratinib when considering annual costs. Adopted in combination, total therapy costs increase accordingly.
3. Is there potential for biosimilar competition within the next five years?
No, due to patent protections and data exclusivities, biosimilars are unlikely until at least 2028.
4. What is the primary market for Tucatinib?
US and European markets, where HER2-positive breast cancer prevalence is highest, represent the primary revenue bases.
5. Could clinical trial results alter the economic outlook?
Yes, positive results expanding indications could increase utilization, raising revenues without necessarily impacting pricing structure.
References
[1] IQVIA. (2022). Pharmaceutical Market Reports.
[2] FDA. (2021). Tucatinib (Hudh) New Drug Application.
[3] EvaluatePharma. (2022). World Market Outlook for HER2+ Breast Cancer Treatments.
